Structure-Function Studies of Sponge-Derived Compounds on the Cardiac CaV3.1 Channel

T-type calcium (CaV3) channels are involved in cardiac automaticity, development, and excitation–contraction coupling in normal cardiac myocytes. Their functional role becomes more pronounced in the process of pathological cardiac hypertrophy and heart failure. Currently, no CaV3 channel inhibitors are used in clinical settings. To identify novel T-type calcium channel ligands, purpurealidin analogs were electrophysiologically investigated. These compounds are alkaloids produced as secondary metabolites by marine sponges, and they exhibit a broad range of biological activities. In this study, we identified the inhibitory effect of purpurealidin I (1) on the rat CaV3.1 channel and conducted structure–activity relationship studies by characterizing the interaction of 119 purpurealidin analogs. Next, the mechanism of action of the four most potent analogs was investigated. Analogs 74, 76, 79, and 99 showed a potent inhibition on the CaV3.1 channel with IC50’s at approximately 3 μM. No shift of the activation curve could be observed, suggesting that these compounds act like a pore blocker obstructing the ion flow by binding in the pore region of the CaV3.1 channel. A selectivity screening showed that these analogs are also active on hERG channels. Collectively, a new class of CaV3 channel inhibitors has been discovered and the structure–function studies provide new insights into the synthetic design of drugs and the mechanism of interaction with T-type CaV channels.


Introduction
T-type calcium channels are members of the superfamily of voltage-gated calcium (Ca V ) channels. These channels are represented by three genes that encode three different Ca V 3 α1-subunits [1,2]. The Ca V 3.1 (α1G) and Ca V 3.2 (α1H) T-type Ca V channel isoforms are present mainly in the heart [3]. However, it has been shown that Ca V 3.3 (α1I) channels are also expressed in Purkinje fibers [4]. The Ca V 3 channels are involved in cardiac automaticity, development, and excitation-contraction coupling in normal cardiac myocytes. Their functional role becomes more pronounced in the process of pathological cardiac hypertrophy and heart failure [5][6][7]. Studies have shown that Ca V 3.1 knockout mice present with bradycardia, confirming the role of these channels in pacemaking activity [8,9]. Mice lacking Ca V 3.2, unlike mice lacking Ca V 3.1, showed severely suppressed pressure overload-induced hypertrophy. Furthermore, angiotensin II-induced cardiac hypertrophy

Structure-Activity Relationship of Sponge-Derived Compounds
Secondary metabolites of marine sponges are known to possess a wide array of interesting bioactivities and, therefore, their effect on the cardiac T-type CaV channel CaV3.1 was evaluated. A first screening of purpurealidin I (1) (Figure 1) showed that this alkaloid was able to potently inhibit the rat CaV3.1 channel (Figure 2). In previous work, a library of 119 simplified analogs was synthesized with the aim of targeting KV10.1 [18,[23][24][25]. Due to the interesting activity of purpurealidin I (1), we decided to repurpose this existing library to investigate the structure-activity relationship with respect to the CaV3.1 channels. All compounds were first dissolved in DMSO and then diluted in a 10 mM Ba 2+ solution. Compounds were tested at a final concentration of 10 µM. A first series of compounds is shown in Table S1. Compounds 2-12 are simplified analogs that show modifications to the bromotyramine part of the structure of purpurealidin I ( Figure 1 and Table S1). The synthesis of these bromotyrosine analogs is described in more detail by Bhat et al. [24]. The average current inhibition (%) is shown in Figure 2.  1-12). Compounds were tested at 10 µM. Data are presented as means ± SEM (n ≥ 3). Statistical significance was determined using one-way ANOVA with Dunnett's post-test; ** p < 0.01; **** p < 0.0001. The inset 1 9 Figure 1. Structure of purpurealidin I (compound 1) [22].

Structure-Activity Relationship of Sponge-Derived Compounds
Secondary metabolites of marine sponges are known to possess a wide array of interesting bioactivities and, therefore, their effect on the cardiac T-type CaV channel CaV3.1 was evaluated. A first screening of purpurealidin I (1) (Figure 1) showed that this alkaloid was able to potently inhibit the rat CaV3.1 channel (Figure 2). In previous work, a library of 119 simplified analogs was synthesized with the aim of targeting KV10.1 [18,[23][24][25]. Due to the interesting activity of purpurealidin I (1), we decided to repurpose this existing library to investigate the structure-activity relationship with respect to the CaV3.1 channels. All compounds were first dissolved in DMSO and then diluted in a 10 mM Ba 2+ solution. Compounds were tested at a final concentration of 10 µM. A first series of compounds is shown in Table S1. Compounds 2-12 are simplified analogs that show modifications to the bromotyramine part of the structure of purpurealidin I (Figure 1 and Table S1). The synthesis of these bromotyrosine analogs is described in more detail by Bhat et al. [24]. The average current inhibition (%) is shown in Figure 2.  1-12). Compounds were tested at 10 µM. Data are presented as means ± SEM (n ≥ 3). Statistical significance was determined using one-way ANOVA with Dunnett's post-test; ** p < 0.01; **** p < 0.0001. The inset 1 9 Figure 2. Inhibition of Ca V 3.1 after application of purpurealidin analogs (compounds 1-12). Compounds were tested at 10 µM. Data are presented as means ± SEM (n ≥ 3). Statistical significance was determined using one-way ANOVA with Dunnett's post-test; ** p < 0.01; **** p < 0.0001. The inset shows representative Ca V 3.1 current traces in control (black) and after application of 10 µM compound 1 or compound 9 (blue).
A first series of compounds is shown in Table S1. Compounds 2-12 are simplified analogs that show modifications to the bromotyramine part of the structure of purpurealidin I ( Figure 1 and Table S1). The synthesis of these bromotyrosine analogs is described in more detail by Bhat et al. [24]. The average current inhibition (%) is shown in Figure 2.
A first screening showed potent inhibition of Ca V 3.1 currents by purpurealidin I (compound 1, 70.5 ± 0.6%). For the simplified analogs, only compound 9 (15.1 ± 3.1%) showed a low but significant inhibition of the Ca V 3.1 channels. Purpurealidin I (1) showed the strongest inhibition of Ca V 3.1 currents at 10 µM, but unfortunately, not enough material was available to determine a concentration-response curve for this compound.
Next, compounds 13-40 (Table S2) are simplified analogs that show modifications to the bromotyrosine part of the purpurealidin I (1) structure ( Figure 1). More specifically, these compounds are simpler amide analogs containing the tyramine fragment in combination with substituted phenyl rings (Ar in Table S2). The synthesis of these bromotyramine analogs is described in more detail by Moreels et al. [18]. The average current inhibition (%) is shown in Figure 3.
showed a low but significant inhibition of the CaV3.1 channels. Purpurealidin I (1) showed the strongest inhibition of CaV3.1 currents at 10 µM, but unfortunately, not enough material was available to determine a concentration-response curve for this compound.
Next, compounds 13-40 (Table S2) are simplified analogs that show modifications to the bromotyrosine part of the purpurealidin I (1) structure ( Figure 1). More specifically, these compounds are simpler amide analogs containing the tyramine fragment in combination with substituted phenyl rings (Ar in Table S2). The synthesis of these bromotyramine analogs is described in more detail by Moreels et al. [18]. The average current inhibition (%) is shown in Figure 3. . Compounds were tested at 10 µM. Data are presented as means ± SEM (n ≥ 3). Statistical significance was determined using one-way ANOVA with Dunnett's post-test; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
Compounds 41-72 (Table S3) consist of synthesized marine bromotyrosine clavatadine C 41 and its spiro-structured analogs, which here are called spirocyclic bromotyrosines. Structurally, these analogs are more rigid and occupy the chemical space better than the open-chain bromotyrosine. The synthesis of these compounds is described in more detail by Patel et al. [23]. Synthesis of chloro spiro compounds 65-72 is described in the supporting material (Supplemental Scheme S1). The average current inhibition (%) is shown in Figure 4.  . Compounds were tested at 10 µM. Data are presented as means ± SEM (n ≥ 3). Statistical significance was determined using one-way ANOVA with Dunnett's post-test; * p < 0.05; ** p < 0.01; *** p < 0.001.

Electrophysiological Characterization of Compounds 74, 76, 79, and 99 on the T-Type Cav Channels
The activity of the purpurealidin compounds 74, 76, 79 and 99 ( Figure 7) was investigated using electrophysiology on oocytes that expressed the CaV3.1 channel. In a first stage, an electrophysiological characterization was conducted for compounds 74, 76, and 79. The concentration-dependency of the inhibition was evaluated using increasing compound concentrations on all three CaV3 isoforms ( Figure 8). The calculated IC50 values and Hill coefficients are shown in Table 1.   In a first stage, an electrophysiological characterization was conducted for compounds 74, 76, and 79. The concentration-dependency of the inhibition was evaluated using increasing compound concentrations on all three Ca V 3 isoforms ( Figure 8). The calculated IC 50 values and Hill coefficients are shown in Table 1.

Electrophysiological Characterization of Compounds 74, 76, 79, and 99 on the T-Type Cav Channels
The activity of the purpurealidin compounds 74, 76, 79 and 99 (Figure 7) was investigated using electrophysiology on oocytes that expressed the CaV3.1 channel. In a first stage, an electrophysiological characterization was conducted for compounds 74, 76, and 79. The concentration-dependency of the inhibition was evaluated using increasing compound concentrations on all three CaV3 isoforms ( Figure 8). The calculated IC50 values and Hill coefficients are shown in Table 1.
Further electrophysiological characterization was performed with a compound concentration of 10 µM. Current traces of the Ca V 3 channel isoforms before (control, black) and after the application of 10 µM compound (blue) are shown in the top row of Figure 9A for compound 74, the top row of Figure 9B for compound 76, and the top row of Figure 9C for compound 79. In the middle row of each panel, the normalized current amplitude (I/I max,control ) in control conditions (black circles) and compound conditions (blue circles) 7 of 15 is plotted against the pulse potential. To evaluate the effect of the compounds on the activation and inactivation of Ca V 3 channels, the normalized current amplitude (I/I max ) is plotted against the corresponding pulse potentials and fitted with the Boltzmann equation (Figure 9, bottom row of each panel). No significant shift in the voltage dependency of the Ca V 3 channels was observed upon compound binding (Figure 9, middle and bottom row of each panel). Wash-in and wash-out studies showed that the binding of these compounds to the Ca V 3 channels is reversible (Supplemental Figure S1). 10 µM compound. In 10 mM Ba 2+ , currents were elicited by depolarizing pulses from −90 to +50 mV for Ca V 3.1 and Ca V 3.2, and from −90 to +40 mV for Ca V 3.3. Holding potential was −90 mV. First 300 ms of the depolarizing pulses are shown for Ca V 3.1 and Ca V 3.2, and 600 ms for Ca V 3.3. Middle row: Normalized voltage-current relationship in control (black symbols) and compound (10 µM, blue symbols) conditions. Bottom row: steady-state activation (open symbols) and inactivation (closed symbols) curves in control (black symbols) and compound (10 µM, blue symbols) conditions. Data are presented as means ± SEM (n ≥ 3).
In the next stage of the structure-activity relationship studies, we discovered that compound 99 could potently inhibit the Ca V 3.1 channels. Moreover, for this compound, an electrophysiological characterization was conducted.
First, the concentration-dependent inhibitory effect of compound 99 was determined by measuring the current inhibition in the presence of increasing compound concentrations. The calculated IC 50 value and the Hill coefficient of compound 99 on Ca V 3.1 are 4.1 ± 0.1 µM and 1.6 ± 0.1, respectively. To investigate isoform selectivity between the two cardiac Ca V 3 channels, the IC 50 value and Hill coefficient were also determined for Ca V 3.2. The IC 50 value is 2.3 ± 0.5 µM with a Hill coefficient of 1.4 ± 0.3. Further electrophysiological characterization was performed with 5 µM of compound 99 on the Ca V 3.1 channel.
Representative current traces of Ca V 3.1 are shown in control conditions (black line) and after application of 5 µM compound 99 (blue line, Figure 10A). At a concentration of 5 µM, Ca V 3.1 currents are inhibited by 57.0 ± 5.8%. The normalized current amplitude (I/I max,control ) in control conditions (black circles) and compound conditions (blue circles) is plotted against the pulse potential ( Figure 10B). Next, the effect of the compounds on the activation and inactivation of the Ca V 3.1 channels is investigated by plotting the normalized current amplitude (I/I max ) against the corresponding pulse potentials and by fitting this with the Boltzmann equation. Steady-state activation and inactivation curves showed no significant shift in the voltage dependency of Ca V 3.1 channels upon compound binding ( Figure 10B,C). For the midpoint of activation, V 1/2 values yielded −39.9 ± 0.1 mV in control conditions and −37.4 ± 0.1 mV in the presence of 5 µM compound 99. For the inactivation curves, the V 1/2 shifted from −56.0 ± 0.1 mV to −53.0 ± 0.2 mV in control and compound situations, respectively. In Figure 10D, a representative normalized timedependent profile of the Ca V 3.1 currents during wash-in and wash-out studies of 5 µM compound 99 is shown for one experiment. The effect of the compound was not completely reversible upon wash-out with compound-free bath solution ( Figure 10D). Unfortunately, due to the limited amount available, compound 99 could not be tested on Ca V 3.3 channels.

Selectivity Screening
As these purpurealidin analogs represent a new class of potent Ca V 3.1 inhibitors, they could potentially be used as pharmacological tools to investigate the role of Ca V 3 channels in various disease models. Therefore, compounds 74, 76, 79, and 99 were further evaluated at a concentration of 10 µM for their selectivity against cardiac voltage-gated potassium and sodium channels. No significant inhibition was observed for compounds 74, 76, 79, and 99 against K V 1.4, K V 4.2 and Na V 1.5 channels. Nevertheless, the affinity for the K V 11.1 channel is an important issue for all four compounds ( Table 2). Table 2. Percentages of inhibition of the selectivity screening of the selected compounds against cardiac voltage-gated potassium and sodium channels at a concentration of 10 µM. Data are presented as means ± SEM (n ≥ 3). NS-not significant.

Structure-Activity Relationship
In this study, we report the identification and characterization of a new group of Ca V 3 channel blockers. These compounds are analogs based on the structure of purpurealidin I (1). Both the bromotyrosine and bromotyramine parts of the structure have been investigated.
In the first series of compounds (Table S1), the bromotyramine part of the purpurealidin I structure was modified. Only compound 9 showed a low but significant inhibition of 15.1 ± 3.1%. An interesting comparison in structure can be made between purpurealidin I (1) and compound 4. Although their bromotyrosine part is identical, the bromotyramine part of these compounds shows a few differences. The aryl group of compound 1 contains two bromine atoms in the meta position, whereas compound 4 contains only one. Furthermore, compound 4 lacks an ethylmethylamine group that is present in compound 1. Finally, the linker between hydroxyamino amide and the aryl group of compound 1 contains two carbon atoms, whereas this linker is missing in compound 4. These modifications cause a difference in inhibition of approximately 70%. When the structure of compound 4 is compared to the structure of compound 9, only a small difference in structure can be noticed. Compound 4 is halogenated with a bromine atom, whereas compound 9 is halogenated with a chlorine atom, causing a shift in effect from not significant (compound 4) to significant (compound 9) inhibition of the Ca V 3.1 currents.
In the next series of compounds (Table S2), structural changes have been made to the bromotyrosine part of purpurealidin I (1). The three most potent compounds from this series are compounds 31, 33, and 37, as they produce 42.4 ± 5.3%, 64.1 ± 6.4%, and 33.5 ± 5.6% inhibition, respectively. Remarkably, all three analogs show a minor difference in the structure that sets them apart from the other compounds in this series. They have a monomethylamine at the end of the propoxy chain, which is identical to the purpurealidin I (1) structure, whereas this is replaced by an N,N-dimethylamino moiety in the other compounds, except for compound 26. In compounds 16 and 19, the monomethylamine is replaced by isopropyl, and no significant effect could be observed. Nonetheless, it is uncertain whether the loss of activity can be attributed to this or to the para-methoxy group that is missing in the aryl group (Ar). Between the three analogs 31, 33, and 37, the only difference is the halogenation of the meta-position, which influences the activity as follows: dihalogenation with chlorine atoms (compound 33) > monohalogenation with a chlorine atom (compound 31) > dihalogenation with fluorine atoms (compound 37). It appears that compounds dihalogenated with chlorine atoms show a greater effect. A similar effect is seen when two other compounds are compared: compound 30 is monohalogenated with a chlorine atom and caused 8.7 ± 4.2% inhibition; compound 32 is dihalogenated with chlorine atoms and inhibited the channels with 26.9 ± 3.0%. Although the tyrosine part of compound 1 is halogenated with two bromine atoms, halogenation with bromine or iodine atoms appears to cause a loss of activity for this series of analogs. Further investigation is required to understand the structurally important moieties in detail.
The third series of compounds (Table S3) include the spirocyclic bromotyrosines. For these analogs, the open chain of the bromotyrosine part is rendered spirocyclic, and the bromotyramine part is replaced by different side chains. Although seven analogs retained some significant activity, it appears that the spirocyclic structure causes a decrease in activity. This difference could be attributed to the more rigid structure of the spirocyclic bromotyrosine analogs. Because there are no large differences in activity between the analogs of this series, it is difficult to determinate any SAR. One thing we could confirm is the importance of halogenation. Non-halogenated compounds showed no significant effect. For the halogenated compounds, no significant difference was observed between bromine or chlorine dihalogenation for compounds with identical R-groups, for example, compounds 48 and 65, compounds 53 and 68, compounds 55 and 66, and compounds 56 and 67. However, a significant difference was observed between the activity of compound 68 (21.7 ± 6.7% inhibition) and the activity of compounds 58 (3.7 ± 2.0% inhibition) and 72 (3.1 ± 1.1% inhibition). Remarkably, there is only a minor structural difference. All three compounds contain the same pyridine ring, but the pyridine ring of compound 68 is immediately linked to the amide. However, compounds 58 and 72 contain a methylene unit between the pyridine ring and the amide, which completely abolishes the effect.
Finally, the last series comprises the diarylamine analogs (Table S4). Compound 99 is the most active compound of this series, with an inhibition of 90.7 ± 5.4%. This analog has a unique structure compared to other analogs of this series. Although the diarylamine group is a common feature among most compounds, it is replaced by a diarylether group in compound 99. Other features of this compound include an orthonitro and para-trifluoromethyl substituent on the phenyl ring (R1 and R2 in Table S4). Furthermore, at the end of the aliphatic chain is a basic dimethylamine group (R3 in  Table S4), and finally, the aliphatic chain between the aromatic ring and the basic center contains a hydroxy group (R4 in Table S4). An interesting comparison can be made between compounds 99 and 76. The latter compound shares the same features as compound 99, with the only exception that it contains the diarylamine structure instead of the diarylether group. This structural difference reduced the activity of compound 76 by half compared to compound 99. Another noteworthy comparison can be made between compounds 76 and 79. Removal of the nitro group on the phenyl ring of compound 76 causes an increase in activity by approximately 20% for compound 79, although this difference was not shown to be significant. When the nitro group on the phenyl ring is replaced by a methyl ester (compound 81), no difference in activity could be observed. However, compound 77, in which the nitro group is replaced by an amino group, lost approximately 20% activity compared to compound 76. For two analogs, compounds 73 and 74, the hydroxy group was removed. Despite this structural modification, no difference in effect was observed between these compounds and their analogs that contain the hydroxy group (compounds 75 and 76, respectively). Furthermore, a significant increase in activity was observed for compounds that contain a para-trifluoromethyl group versus the ones without, for example, compounds 73 and 74, 75 and 76, 78 and 79, and 80 and 81. Replacement of the amine linker between the two aryl groups by an amide, resulting in an N-aryl-arylamide structure (such as compounds 102 and 103), abolished all activity. Finally, it appears that compounds with a large group at the end of the aliphatic chain are less potent. This is observed in compounds with a morpholino moiety (such as compounds 88-93) or an aniline moiety (compound 94), or even in larger groups such as compounds 95-98. Remarkably, a structural difference was noticed that is similar to what is earlier described for the bromotyramine analogs (second series, Table S2). Namely, at the end of the aliphatic chain, compound 85 contains a monomethylamine that is identical to the purpurealidin I (1) structure, causing a higher percentage of inhibition than its analogous compound with an N,N-dimethylamino moiety (compound 76).
The other diarylamine analogs (Table S5) show no big changes in effect, although a few differences may be worth mentioning. First, no significant difference in activity was observed upon non-halogenation, bromine dehalogenation, or chlorine dihalogenation of the aryl ring. Next, compound 104 shows a structure that is comparable with compound 74. They both contain an ortho-nitro and para-trifluoromethyl substituent on the phenyl ring, and they do not show a hydroxy group on their aliphatic chain. The only difference is that the aliphatic chain of compound 104 lacks one carbon atom compared to compound 74. This causes a reduction in activation for compound 104 by approximately 30%. Lastly, compounds 115-119 have an N-aryl-arylamide structure, contain a phenyl ring directly linked to the ether that connects it to the aryl ring, and show alterations in the positioning of the nitro groups. Those differences in structure caused a complete loss of activity. However, further structure-function studies are required to draw more definite conclusions.

Electrophysiological Characterization
After observing the interesting effect of compounds 74, 76, 79, and 99 on Ca V 3.1 channels, further characterization was conducted. The calculated IC 50 values yielded 2.6 ± 0.6 µM, 3.7 ± 0.6 µM, 5.9 ± 1.9 µM, and 4.1 ± 0.1 µM, respectively. No significant difference between these values was observed, although, at a concentration of 10 µM, the effect of compound 99 was significantly higher. These variances may be explained by differences in the properties of the compounds. Namely, the effect of compounds 74, 76, and 79 on all three Ca V 3 channels were shown to be reversible, but this seemed not the case for compound 99. After up to ten minutes of washing out with a compound-free solution, the effect of the compound was still present. Furthermore, our electrophysiological studies suggested that these compounds act like a pore blocker obstructing the ion flow by binding in the pore region of the Ca V 3.1 channel rather than acting as a voltage-sensor modifier because no significant shift in the activation and steady-state inactivation curves could be observed.
Zhao et al. observed a similar phenomenon, in that the Z944 compound acted as a pore blocker on the Ca V 3.1 channel [27]. After detailed investigations, they showed that the Z944 compound exhibited an arch-shaped conformation, reclining in the central cavity of the pore domain, with its wide end embedded in the II-III fenestration and its narrow end situated above the intracellular gate like a plug [27]. It may be noticed that the structure of purpurealidin I (1) and compound 99 resembles the Z944 structure ( Figure 11). This could indicate that our compounds share the same binding location, which would be consistent with our findings that the compounds are pore blockers of the Ca V 3.1 channel. binding in the pore region of the CaV3.1 channel rather than acting as a voltage-sensor modifier because no significant shift in the activation and steady-state inactivation curves could be observed. Zhao et al. observed a similar phenomenon, in that the Z944 compound acted as a pore blocker on the CaV3.1 channel [27]. After detailed investigations, they showed that the Z944 compound exhibited an arch-shaped conformation, reclining in the central cavity of the pore domain, with its wide end embedded in the II-III fenestration and its narrow end situated above the intracellular gate like a plug [27]. It may be noticed that the structure of purpurealidin I (1) and compound 99 resembles the Z944 structure ( Figure 11). This could indicate that our compounds share the same binding location, which would be consistent with our findings that the compounds are pore blockers of the CaV3.1 channel. Figure 11. Structures of Z944, purpurealidin I (1), and compound 99.

Selectivity Screening
In the last part of this study, analogs 74, 76, 79, and 99 were evaluated for their selectivity against other cardiac ion channels, in particular the KV11.1 channel. The currents of potassium channels, KV1.4 and KV4.2, and the sodium channel, NaV1.5, play an important role in the generation of action potentials in the heart [28]. Therefore, the effect of the compounds was investigated on these channels, but no activity could be observed. What is of concern, however, is their activity on KV11.1 channels. All four compounds were shown to potently inhibit hERG channels.

Selectivity Screening
In the last part of this study, analogs 74, 76, 79, and 99 were evaluated for their selectivity against other cardiac ion channels, in particular the K V 11.1 channel. The currents of potassium channels, K V 1.4 and K V 4.2, and the sodium channel, Na V 1.5, play an important role in the generation of action potentials in the heart [28]. Therefore, the effect of the compounds was investigated on these channels, but no activity could be observed. What is of concern, however, is their activity on K V 11.1 channels. All four compounds were shown to potently inhibit hERG channels.
Whereas compound 99 is equipotent across Ca V 3.1 and hERG channels, Z944 is 150-fold more potent against Ca V 3.1 compared to hERG channels. Remarkably, the hERG activity of compound 99 (69.1 ± 1.9% at a concentration of 10 µM) is comparable to the hERG activity of Z944 (IC 50 = 7.8 µM).
This selectivity issue is of major concern during drug development projects. Inhibition of the hERG channel can cause prolongation of the AP and lead to an increase in the length of time between the start of the Q-wave and the end of the T-wave on an electrocardiogram (QT interval), resulting in lethal cardiac arrhythmia, e.g., Torsade de Pointes (TdP) [29]. Jamieson et al. summarized different in vitro, in vivo, and in silico approaches to determine and overcome hERG blockade. They suggest disrupting any putative π-stacking interactions with the channel, which, in the case of compound 99, could be related to its diarylether group. Furthermore, they propose attenuating hERG inhibition by creating subtle changes in the molecular architecture, such as by removing electron-donating groups, adding electron-withdrawing moieties, or modifying the template of the structure, such as by deleting distal aromatic groups or incorporating heterocyclic groups [29]. These techniques can be used in the future to further optimize our lead compounds. Moreover, the published cryo-EM structure of the hERG channel can help in predicting the hERG liability of compounds [30].

Compound Synthesis
For this study, we made use of an existing library of purpurealidin analogs. These compounds were chemically synthesized in previous studies, as described in detail by Moreels et al. [18], Patel et al. [23], Bhat et al. [24], Toplak et al. [25], and Gubič et al. [26]. Synthesis of compounds 65-72 and 115-120 is described in the supporting material.

Xenopus Laevis Surgery
Stage V-VI oocytes were isolated via partial ovariectomy from X. laevis frogs (African clawed frogs), as described previously [31]. Mature female frogs were purchased from CRB Xénopes (Rennes, France) and housed in the Aquatic Facility (KU Leuven) in compliance with the regulations of the European Union (EU) concerning the welfare of laboratory animals, as declared in Directive 2010/63/EU. After the frogs were anesthetized by a 15 min submersion in 0.1% tricaine methanesulfonate (pH 7.0), the oocytes were collected. The isolated oocytes were then washed with a 1.5 mg/mL collagenase solution to remove the follicle layer.

Expression of Ca V 3 Channels in Xenopus Laevis Oocytes
Rat Ca V 3.1, human Ca V 3.2, rat Ca V 3.3, human Na V 1.5, rat K V 1.4, rat K V 4.2, and human K V 11.1 were expressed in X. laevis oocytes by linearizing the plasmids and subsequent in vitro transcription using a commercial T7 mMESSAGE mMACHINE transcription kit (Ambion, Carlsbad, CA, USA). Defolliculated Xenopus oocytes were injected with 50 nL of cRNA at a concentration of 1 ng/nL by using a microinjector (Drummond Scientific Company, Broomall, PA, USA). The oocytes were incubated in a solution containing (in mM): NaCl, 96; KCl, 2; CaCl 2 , 1.8; MgCl 2 , 2; and HEPES, 5 (pH 7.5). This solution was supplemented with 50 mg/L gentamicin sulfate and 90 mg theophylline.

Electrophysiological Recordings
Two-electrode voltage clamp recordings were performed at room temperature (18-22 • C) by using a GeneClamp 500 amplifier (Molecular Devices, San Jose, CA, USA) controlled by a pClamp data acquisition system (Axon Instruments, Union City, CA, USA). Whole-cell currents from oocytes were recorded 5-10 days after mRNA injection. The bath solution composition was the following (in mM): BaCl 2 , 10; NaOH, 90; KOH, 1; EDTA, 0.1; and HEPES, 5 (pH 7.5). Voltage and current electrodes were filled with 3 M KCl. Resistances of both electrodes were kept between 0.8 and 1.5 MΩ. The elicited Ca V 3.1, Ca V 3.2, and Ca V 3.3 currents were filtered at 2 kHz and sampled at 4 kHz using a four-pole low-pass Bessel filter. Leak subtraction was performed by using a -P/4 protocol. Oocytes were placed in a measuring chamber filled with 200 µL ND96. The compounds were added directly to the measuring chamber under continuous application of the described voltage protocol. The percentage channel modulation was calculated when steady-state conditions were reached.
For the electrophysiological analysis of peptides, a number of protocols were applied from a holding potential of −90 mV. Currents for Ca V 3.1 and Ca V 3.2, which were carried by Ba 2+ , were evoked by 300 ms depolarizing pulses to −25 mV or Vmax (the voltage corresponding to maximal Ba 2+ current in control conditions). Currents for Ca V 3.3, which were carried by Ba 2+ , were evoked by 1 s depolarizing pulses to −25 mV or Vmax. The current-voltage relationships were determined by 600 ms step depolarizations between −90 and +60 mV, using 10 mV increments. The values of I PBa were normalized to the maximal Ba 2+ current amplitude and plotted as a function of voltage. To investigate the effect of the peptide toxins on the activation and steady-state inactivation, a standard 2-step protocol was used. In this protocol, 600 ms conditioning 10 mV step prepulses, ranging from −90 to +60 mV, were followed by a 400 ms test pulse to −25 mV. Data were normalized to the maximal Ba 2+ current amplitude, plotted against prepulse potential, and fitted by using the Boltzmann function: where I max is the maximal I Ba , V h is the voltage corresponding to half-maximal inactivation, V is the test voltage, k is the slope factor, and C is a constant representing a non-inactivating persistent fraction (close to 0 in control). The concentration-response relationship was determined by fitting the data with the Hill equation: y = 100/{1 + [IC 50 /(toxin)] h }, where y is the amplitude of the toxin-induced effect, IC 50 is the toxin concentration at half-maximal efficacy, toxin is the toxin concentration, and h is the Hill coefficient.
The selectivity screening was conducted with the following protocols: the elicited K V 1.4, K V 4.2, and K V 11.1 currents were filtered at 0.5 kHz and sampled at 2 kHz; Na V 1.5 currents were filtered at 2 kHz and sampled at 20 kHz using a four-pole low-pass Bessel filter. Leak subtraction was performed using a -P/4 protocol. The oocytes were measured in a bath solution composition of ND96 (in mM): NaCl, 96; KCl, 2; CaCl 2 , 1.8; MgCl 2 , 2; and HEPES, 5 (pH 7.5). For the electrophysiological analysis of the compounds, a number of protocols were applied from a holding potential of −90 mV. Currents for K V 1.4 and K V 4.2 were evoked by 0.5 s depolarizing pulses to 0 mV, followed by 0.5 s repolarizing pulses to −50 mV. Currents for K V 11.1 were evoked by 2.5 s depolarizing prepulses to +40 mV, followed by hyperpolarizing pulses to −120 mV for 2.5 s. Currents for Na V 1.5 were evoked by 100 ms depolarizing pulses to 0 mV.

Conclusions
In this study, we discovered a new class of Ca V 3 inhibitors. The effect of the spongederived purpurealidin I (1) compound and 119 bromotyrosine analogs were examined using two-electrode voltage clamp electrophysiology on oocytes expressing the Ca V 3.1 channel.
Although some conclusions could be drawn, additional studies are still required to further analyze and correlate differences in structure with differences in activity on the Ca V 3.1 channel. Moreover, molecular modeling can be used to determine the binding location of these compounds in the Ca V 3.1 channel. Further electrophysiological characterization was conducted with potent inhibitor compounds 74, 76, 79, and 99. Our data suggest that these compounds act on the channel as pore blockers.